Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction

Sally Lee, Daniel Glicklich, Maria Coco

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. Pamidronate is a second-generation bisphosphonate that has been used to attenuate post-renal transplant bone loss, but its effect on the function of the renal allograft is unclear. Therefore, we evaluated the long-term renal function in 57 subjects who had participated in a prospective, randomized clinical trial using pamidronate to attenuate bone loss in the renal transplant recipient. Methods. Thirty subjects (PAM) received intravenous pamidronate, 60 mg at baseline post-transplant and 30 mg in months 1, 2, 3 and 6 post-transplant, while 27 subjects (CON) did not receive pamidronate. We followed renal function, need for renal replacement therapy following transplant rejection, and mortality for 3 years following the start of the original study. Results. PAM did not have increased incidence of renal dysfunction or mortality compared with CON at any time point during the 3 years of follow-up. The incidence of proteinuria was also not different between the two groups. Conclusions. The prophylactic use of pamidronate in the above doses to attenuate bone loss in renal transplant recipients is not associated with higher incidence of renal dysfunction or mortality in a 3 year follow-up study. These findings may support the use of bisphosphonates in the treatment of early renal transplant-related bone loss.

Original languageEnglish (US)
Pages (from-to)2870-2873
Number of pages4
JournalNephrology Dialysis Transplantation
Volume19
Issue number11
DOIs
StatePublished - Nov 2004

Fingerprint

pamidronate
Transplants
Kidney
Bone and Bones
Diphosphonates
Mortality
Incidence
Renal Replacement Therapy
Graft Rejection

Keywords

  • Bisphosphonates
  • Renal osteodystrophy
  • Renal transplant

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction. / Lee, Sally; Glicklich, Daniel; Coco, Maria.

In: Nephrology Dialysis Transplantation, Vol. 19, No. 11, 11.2004, p. 2870-2873.

Research output: Contribution to journalArticle

@article{5e5bc64260a54958a4c44cd20c0c4e43,
title = "Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction",
abstract = "Background. Pamidronate is a second-generation bisphosphonate that has been used to attenuate post-renal transplant bone loss, but its effect on the function of the renal allograft is unclear. Therefore, we evaluated the long-term renal function in 57 subjects who had participated in a prospective, randomized clinical trial using pamidronate to attenuate bone loss in the renal transplant recipient. Methods. Thirty subjects (PAM) received intravenous pamidronate, 60 mg at baseline post-transplant and 30 mg in months 1, 2, 3 and 6 post-transplant, while 27 subjects (CON) did not receive pamidronate. We followed renal function, need for renal replacement therapy following transplant rejection, and mortality for 3 years following the start of the original study. Results. PAM did not have increased incidence of renal dysfunction or mortality compared with CON at any time point during the 3 years of follow-up. The incidence of proteinuria was also not different between the two groups. Conclusions. The prophylactic use of pamidronate in the above doses to attenuate bone loss in renal transplant recipients is not associated with higher incidence of renal dysfunction or mortality in a 3 year follow-up study. These findings may support the use of bisphosphonates in the treatment of early renal transplant-related bone loss.",
keywords = "Bisphosphonates, Renal osteodystrophy, Renal transplant",
author = "Sally Lee and Daniel Glicklich and Maria Coco",
year = "2004",
month = "11",
doi = "10.1093/ndt/gfh504",
language = "English (US)",
volume = "19",
pages = "2870--2873",
journal = "Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction

AU - Lee, Sally

AU - Glicklich, Daniel

AU - Coco, Maria

PY - 2004/11

Y1 - 2004/11

N2 - Background. Pamidronate is a second-generation bisphosphonate that has been used to attenuate post-renal transplant bone loss, but its effect on the function of the renal allograft is unclear. Therefore, we evaluated the long-term renal function in 57 subjects who had participated in a prospective, randomized clinical trial using pamidronate to attenuate bone loss in the renal transplant recipient. Methods. Thirty subjects (PAM) received intravenous pamidronate, 60 mg at baseline post-transplant and 30 mg in months 1, 2, 3 and 6 post-transplant, while 27 subjects (CON) did not receive pamidronate. We followed renal function, need for renal replacement therapy following transplant rejection, and mortality for 3 years following the start of the original study. Results. PAM did not have increased incidence of renal dysfunction or mortality compared with CON at any time point during the 3 years of follow-up. The incidence of proteinuria was also not different between the two groups. Conclusions. The prophylactic use of pamidronate in the above doses to attenuate bone loss in renal transplant recipients is not associated with higher incidence of renal dysfunction or mortality in a 3 year follow-up study. These findings may support the use of bisphosphonates in the treatment of early renal transplant-related bone loss.

AB - Background. Pamidronate is a second-generation bisphosphonate that has been used to attenuate post-renal transplant bone loss, but its effect on the function of the renal allograft is unclear. Therefore, we evaluated the long-term renal function in 57 subjects who had participated in a prospective, randomized clinical trial using pamidronate to attenuate bone loss in the renal transplant recipient. Methods. Thirty subjects (PAM) received intravenous pamidronate, 60 mg at baseline post-transplant and 30 mg in months 1, 2, 3 and 6 post-transplant, while 27 subjects (CON) did not receive pamidronate. We followed renal function, need for renal replacement therapy following transplant rejection, and mortality for 3 years following the start of the original study. Results. PAM did not have increased incidence of renal dysfunction or mortality compared with CON at any time point during the 3 years of follow-up. The incidence of proteinuria was also not different between the two groups. Conclusions. The prophylactic use of pamidronate in the above doses to attenuate bone loss in renal transplant recipients is not associated with higher incidence of renal dysfunction or mortality in a 3 year follow-up study. These findings may support the use of bisphosphonates in the treatment of early renal transplant-related bone loss.

KW - Bisphosphonates

KW - Renal osteodystrophy

KW - Renal transplant

UR - http://www.scopus.com/inward/record.url?scp=8344249468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8344249468&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfh504

DO - 10.1093/ndt/gfh504

M3 - Article

C2 - 15466880

AN - SCOPUS:8344249468

VL - 19

SP - 2870

EP - 2873

JO - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

SN - 0931-0509

IS - 11

ER -